Hot Stocks in the Drug Delivery Industry - Delcath Systems (DCTH), Generex Biotechnology (GNBT), Elan Corporation (ELN)

New York, NY -- (SBWIRE) -- 03/13/2013 -- StockRunway.com issues special report on the Hot Stocks in the Drug Delivery Industry – Delcath Systems, Inc (NASDAQ:DCTH), Generex Biotechnology Corporation (PINK:GNBT), Elan Corporation, plc (ADR) (NYSE:ELN).

Delcath Systems, Inc (NASDAQ:DCTH) shares went -10.33% down and closed at $1.91 in the last trading session on worries regarding Melblez. The Street's latest FDA Drug Approval Contest disclosed that 54 percent of investors who submitted entries expect the FDA panel will slap down Melblez; 46% predict the panel will be positive. The point to be noted was that 64% predict FDA will eventually reject Melblez while 35% says it will be approved.

Has DCTH Found The Bottom and Ready To Move Up? Find Out Here

The stock’s overall traded volume was 6.43 million shares. The stock’s opening price was $2.16, hitting the day high price of $2.18 and day low of $1.86. DCTH has earnings per share of -$1.07. The company has -134.53% returns on assets, -172.66% returns on equity and its return on investments is -170.94%.

Generex Biotechnology Corporation (PINK:GNBT) dropped -6.06% to close at $0.0310 and its total volume in the last trading session was 2.40 million shares, one day after it filed Form 10-K with the SEC. In last 52 weeks, high hit was $0.15 and low price in that period was $0.02.

The company has outstanding shares of 372.06million with the total market cap of $11.53million and its beta value stands at 1.80 times. It has current ratio of 2.00 and its debt-to-equity ratio is 0.33.

Has GNBT Found The Bottom And Ready To Gain Momentum? Find Out Here

Elan Corporation, plc (ADR) (NYSE:ELN) moved up +1.01% and closed at $12.00 with the total traded volume of 3.99 million shares. The company recently said that the Tender Offer documentation for the stock buyback has been filed and is available on the Company’s website at www.elan.com.

On completion of the previously-declared Tysabri Transaction, Elan is set to issue an irrevocable Notice of Redemption to redeem all of the outstanding 6.25% Notes due 2019 at a redemption price equal to 100% of the principal amount of the Notes plus the “Applicable Premium”. Subsequent to the close of the Share Repurchase, the company will satisfy and discharge the Indenture by irrevocably depositing with the Trustee funds in trust enough to pay and fulfill all outstanding Notes on the redemption date.

Shareholders will receive a notice of the shareholder meeting to be held on April 12, 2013 on or about March 18, 2013, to consider the resolution mandatory to put into action the Tender Offer.

For How Long ELN will Fight for Profitability? Read This Trend Analysis report

Its opening price was $11.83 and its shares traded within the range of $11.81-$12.04. This company has earnings per share of -$0.63. The company now has market cap of about $7.17 billion.The stock has positive year-to-date performance of +17.53% and is trading above its 50 day moving average of +13.51% and 200 day moving average of +4.73%.

About StockRunway.com
StockRunway.com is an Elite Financial Stock website catering to individual investors, fund managers, investment bankers and equity analysts. Whether you're new to penny stocks or a seasoned veteran, you'll find all the information you will need right here! Our research is a remarkable educational tool for everyone to utilize.

Sign up TODAY and join the vast amount of investors already benefiting from the best free alerts from StockRunway's service today!

Disclaimer
This report/release/advertisement is a commercial advertisement and is for general information purposes only. Never invest in any stock featured on our site, Press Releases or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: StockRunway.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever. Read our Full Disclaimer by visiting our website.

Read Our Full Disclaimer at: http://www.stockrunway.com/disclaimer/